Type 1 diabetes: current concepts in epidemiology, pathophysiology, clinical care, and research.

Type 1 diabetes (T1D) is an autoimmune disease mediated by a combination of genetic and environmental triggers resulting in lymphocytic infiltration of pancreatic islets, destruction of beta cells, and lifelong dependency on exogenous insulin. Although T1D is prevalent (1 in 300) and its incidence is steadily increasing worldwide (3% per year), the exact gene-environment interactions precipitating the disease remain unknown. Living with T1D is challenging for patients, families, and caregivers. Because of the relative paucity of pediatric endocrinologists, general pediatricians and other subspecialists may occasionally be faced with the task of managing diabetes-related complaints. Herein, we provide a comprehensive review of the natural history, pathophysiology, and contemporary management of T1D. In addition, recent advances in T1D research are discussed.

[1]  M. Foss,et al.  C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. , 2009, JAMA.

[2]  David M Maahs,et al.  Epidemiology of type 1 diabetes. , 2010, Endocrinology and metabolism clinics of North America.

[3]  A. Montag,et al.  Prevention of Autoimmune Diabetes With Nonactivating Anti-CD3 Monoclonal Antibody , 1992, Diabetes.

[4]  P. Novota,et al.  Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset. , 2004, The review of diabetic studies : RDS.

[5]  D. Schatz,et al.  CD3-antibody therapy in new-onset type 1 diabetes mellitus. , 2005, The New England journal of medicine.

[6]  Bruce Buckingham,et al.  Toward closing the loop: an update on insulin pumps and continuous glucose monitoring systems. , 2010, Endocrinology and metabolism clinics of North America.

[7]  B. Vlcek,et al.  Risk factors for developing brain herniation during diabetic ketoacidosis. , 1999, Pediatric neurology.

[8]  M. Foss,et al.  Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. , 2009, JAMA.

[9]  M. Atkinson,et al.  Type 1 diabetes mellitus: etiology, presentation, and management. , 2005, Pediatric clinics of North America.

[10]  E. Bonifacio,et al.  Pancreatic β-Cell Function and Immune Responses to Insulin After Administration of Intranasal Insulin to Humans At Risk for Type 1 Diabetes , 2004 .

[11]  J. Tuomilehto,et al.  Incidence and trends of childhood Type 1 diabetes worldwide 1990–1999 , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[12]  M. Knip,et al.  Intranasally administered insulin intended for prevention of type 1 diabetes—a safety study in healthy adults , 2003, Diabetes/metabolism research and reviews.

[13]  Hee-Sook Jun,et al.  Autoimmune Destruction of Pancreatic β Cells , 2005, American journal of therapeutics.

[14]  J. Silverstein,et al.  Long-term immunoregulatory effects of therapy with corticosteroids and anti-thymocyte globulin. , 1989, Immunopharmacology and immunotoxicology.

[15]  C. Black,et al.  Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. , 2001, Rheumatology.

[16]  Michel Goldman,et al.  Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. , 2005, The New England journal of medicine.

[17]  G. Dahlquist,et al.  Worldwide childhood type 1 diabetes incidence – what can we learn from epidemiology? , 2007, Pediatric diabetes.

[18]  Jeffrey P. Krischer,et al.  Pancreatic Islet Autoantibodies as Predictors of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 , 2009, Diabetes Care.

[19]  E. Mayer-Davis,et al.  The Value of National Diabetes Registries: SEARCH for Diabetes in Youth Study , 2010, Current diabetes reports.

[20]  D. Dunger,et al.  Diabetic ketoacidosis in children and adolescents , 2009 .

[21]  A. Green,et al.  Geographical variation of presentation at diagnosis of Type I diabetes in children: the EURODIAB Study , 2001, Diabetologia.

[22]  Johnny Ludvigsson,et al.  GAD treatment and insulin secretion in recent-onset type 1 diabetes. , 2008, The New England journal of medicine.

[23]  H. Schneider,et al.  CD28 and CTLA‐4 coreceptor expression and signal transduction , 2009, Immunological reviews.

[24]  E. Bonifacio,et al.  Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. , 1999, Diabetes.

[25]  R. Tisch,et al.  Administering glutamic acid decarboxylase to NOD mice prevents diabetes. , 1994, Journal of autoimmunity.

[26]  R. Tisch,et al.  B Lymphocyte Depletion by CD20 Monoclonal Antibody Prevents Diabetes in Nonobese Diabetic Mice despite Isotype-Specific Differences in FcγR Effector Functions1 , 2008, The Journal of Immunology.

[27]  R. Beck.  Effectiveness of Continuous Glucose Monitoring in a Clinical Care Environment , 2009, Diabetes Care.

[28]  S. Virtanen,et al.  The Environmental Determinants of Diabetes in the Young (TEDDY) Study , 2008, Annals of the New York Academy of Sciences.

[29]  N. Young,et al.  Antithymocyte Globulin for Treatment of the Bone Marrow Failure Associated with Myelodysplastic Syndromes , 2002, Annals of Internal Medicine.

[30]  D. Schatz,et al.  Autoimmune markers in diabetes. , 2011, Clinical chemistry.

[31]  M. Knip,et al.  Putative environmental factors in Type 1 diabetes. , 1998, Diabetes/metabolism reviews.

[32]  E. Havrdová,et al.  Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database , 2006, Multiple sclerosis.

[33]  D. Lezotte,et al.  Islet Cell and Other Organ-specific Antibodies in U.S. Caucasians and Blacks with Insulin-dependent Diabetes Mellitus , 1980, Diabetes.

[34]  D. Follmann,et al.  Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. , 2003, JAMA.

[35]  M. Mayes,et al.  High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. , 2002, Blood.

[36]  M. Hadzija,et al.  Association of PTPN22 C1858T and CTLA-4 A49G polymorphisms with Type 1 Diabetes in Croatians. , 2009, Diabetes research and clinical practice.

[37]  G. Eisenbarth,et al.  Islet cell antibody-positive relatives with human leukocyte antigen DQA1*0102, DQB1*0602: identification by the Diabetes Prevention Trial-type 1. , 2000, The Journal of clinical endocrinology and metabolism.

[38]  Fergus J Cameron,et al.  Diabetic ketoacidosis, hyperosmolarity and hypernatremia: are high‐carbohydrate drinks worsening initial presentation? , 2005, Pediatric diabetes.

[39]  Dana Dabelea,et al.  Incidence of diabetes in youth in the United States. , 2007, JAMA.

[40]  M. Mohty,et al.  Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond , 2007, Leukemia.

[41]  M. Musso,et al.  Intense immunosuppressive therapy followed by autologous peripheral blood selected progenitor cell reinfusion for severe autoimmune disease , 2001, American journal of hematology.

[42]  L. Laffel.  Sick-day management in type 1 diabetes. , 2000, Endocrinology and metabolism clinics of North America.

[43]  L. Groop,et al.  Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA). , 2000, The Journal of clinical endocrinology and metabolism.

[44]  C. Mathieu,et al.  Use of an islet cell antibody assay to identify type 1 diabetic patients with rapid decrease in C-peptide levels after clinical onset. Belgian Diabetes Registry. , 2000, Diabetes care.

[45]  S. Johnson,et al.  Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. , 1988, The New England journal of medicine.

[46]  G. Eisenbarth,et al.  Cellular and molecular pathogenesis of type 1A diabetes , 2007, Cellular and Molecular Life Sciences.

[47]  A. Hämäläinen,et al.  Autoimmunity and familial risk of type 1 diabetes , 2002, Current diabetes reports.

[48]  E. Bonifacio,et al.  Brief Communication: Early Appearance of Islet Autoantibodies Predicts Childhood Type 1 Diabetes in Offspring of Diabetic Parents , 2004, Annals of Internal Medicine.

[49]  D. Matthews,et al.  The hospital and home use of a 30‐second hand‐held blood ketone meter: guidelines for clinical practice , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[50]  J. Logothetopoulos,et al.  The Onset and Progression of Pancreatic Insulitis in the Overt, Spontaneously Diabetic, Young Adult BB Rat Studied by Pancreatic Biopsy , 1984, Diabetes.

[51]  J. Bluestone,et al.  Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. , 2007, Endocrinology.

[52]  P. Lacy,et al.  The natural history and predictive value of Mr 64,000 autoantibodies for insulin-dependent diabetes mellitus. , 1990, Journal of autoimmunity.

[53]  Clive Wasserfall,et al.  Autologous umbilical cord blood infusion for type 1 diabetes. , 2008, Experimental hematology.

[54]  S. Mehta,et al.  Contemporary management of patients with type 1 diabetes. , 2010, Endocrinology and metabolism clinics of North America.

[55]  M. Atkinson,et al.  Insulitis and Diabetes in NOD Mice Reduced by Prophylactic Insulin Therapy , 1990, Diabetes.

[56]  Marian Rewers,et al.  The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes , 2007, Proceedings of the National Academy of Sciences.

[57]  M. Atkinson,et al.  Are Insulin Autoantibodies Markers for Insulin-Dependent Diabetes Mellitus? , 1986, Diabetes.

[58]  A. Haqq,et al.  Hyperglycemic hyperosmolar syndrome in children: pathophysiological considerations and suggested guidelines for treatment. , 2011, The Journal of pediatrics.

[59]  T. Gardner,et al.  Novel antigens in type 1 diabetes: The importance of ZnT8 , 2009, Current diabetes reports.

[60]  P. Bingley,et al.  High familial risk and genetic susceptibility in early onset childhood diabetes. , 2002, Diabetes.

[61]  H. Jalahej,et al.  Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. , 2010, Journal of autoimmunity.

[62]  J. Silverstein,et al.  Predictors of control of diabetes: monitoring may be the key. , 2004, The Journal of pediatrics.

[63]  C. Liddle,et al.  The histopathology of the pancreas in Type I (insulin-dependent) diabetes mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom , 1986, Diabetologia.

[64]  R. Klein,et al.  Inherited susceptibility to insulin-dependent diabetes is associated with HLA-DR1, while DR5 is protective. , 1988, Autoimmunity.

[65]  Desmond E. Williams,et al.  The Burden of Diabetes Mellitus Among US Youth: Prevalence Estimates From the SEARCH for Diabetes in Youth Study , 2006, Pediatrics.

[66]  M. Rewers,et al.  Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). , 2004, The Journal of clinical endocrinology and metabolism.

[67]  R. Holman,et al.  UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes , 1997, The Lancet.

[68]  H. Heimpel,et al.  Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. , 2003, Blood.

[69]  M. Redondo,et al.  Genetics of type 1A diabetes. , 2001, Recent progress in hormone research.

[70]  R. LaPorte,et al.  Islet cell autoimmunity in white and black children and adolescents with IDDM. , 1998, Diabetes care.

[71]  C. Mathews,et al.  Immune Depletion With Cellular Mobilization Imparts Immunoregulation and Reverses Autoimmune Diabetes in Nonobese Diabetic Mice , 2009, Diabetes.

[72]  A. Green,et al.  Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005–20: a multicentre prospective registration study , 2009, The Lancet.

[73]  L. Niskanen,et al.  Five-year follow-up of islet cell antibodies in Type 2 (non-insulin-dependent) diabetes mellitus , 1991, Diabetologia.

[74]  G. Eisenbarth,et al.  Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. , 1985, Diabetes research.

[75]  J. Bluestone,et al.  Targeting CD22 Reprograms B-Cells and Reverses Autoimmune Diabetes , 2008, Diabetes.

[76]  J. Shuster,et al.  Autologous Umbilical Cord Blood Transfusion in Very Young Children With Type 1 Diabetes , 2009, Diabetes Care.

[77]  A. Anagnostopoulos,et al.  Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study , 1997, Bone Marrow Transplantation.

[78]  R Malley,et al.  Risk factors for cerebral edema in children with diabetic ketoacidosis. The Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. , 2001, The New England journal of medicine.